Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Carcinoma, Small Cell 1

Interventions

Cisplatin 4Etoposide 2veliparib 1sagopilone 1sacituzumab govitecan 1pomalidomide 1pembrolizumab 1etoposide phosphate 1Topotecan 1Tomography, X-Ray Computed 1Temozolomide 1Rhenium 1Radiation 1Positron-Emission Tomography 1Podophyllotoxin 1Platinum 1Penfluridol 1Pemetrexed 1PT-100 dipeptide 1Histamine Antagonists 1Epinephrine 1Electrocardiography 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Small Cell × PT-100 dipeptide × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡